T1	Statistical-Effect 60 72	the increase
T2	Parameter 76 80	HER3
T3	Parameter 84 107	MAPK pathway inhibitors
T4	Parameter 111 141	BRAF mutant thyroid cell lines
R1	parameterizes Arg1:T2 Arg2:T1	
R2	parameterizes Arg1:T3 Arg2:T1	
R3	parameterizes Arg1:T4 Arg2:T1	
T5	Parameter 396 412	PLX4032 treatmen
T6	Parameter 424 428	HER3
T7	Parameter 433 437	HER2
T8	DepVb 438 443	mRNAs
T9	Statistical-Effect 414 423	increased
R6	provides-input-for Arg1:T8 Arg2:T9	
R4	parameterizes Arg1:T7 Arg2:T8	
R5	parameterizes Arg1:T6 Arg2:T8	
R7	parameterizes Arg1:T5 Arg2:T8	
T10	Parameter 447 492	all six BRAF-mutant thyroid cancer cell lines
R8	parameterizes Arg1:T10 Arg2:T8	
T11	Parameter 553 578	the MEK inhibitor AZD6244
T12	Parameter 607 624	the MEK inhibitor
T13	DepVb 628 652	total HER2, HER3 protein
T14	Parameter 634 638	HER2
T15	Parameter 640 644	HER3
T16	DepVb 660 665	pHER3
T17	Statistical-Effect 671 685	dose dependent
R9	parameterizes Arg1:T12 Arg2:T13	
R10	parameterizes Arg1:T12 Arg2:T16	
R11	parameterizes Arg1:T15 Arg2:T13	
R12	parameterizes Arg1:T14 Arg2:T13	
R13	provides-input-for Arg1:T13 Arg2:T17	
T18	Statistical-Effect 691 711	inversely associated
T19	IndepVb 717 749	the degree of inhibition of pERK
R14	parameterizes Arg1:T19 Arg2:T18	
R15	provides-input-for Arg1:T16 Arg2:T18	
R16	provides-input-for Arg1:T16 Arg2:T17	
R17	provides-input-for Arg1:T13 Arg2:T18	
T20	Parameter 761 782	RAF or MEK inhibitors
T21	Measurement 791 810	luciferase activity
T22	Parameter 814 898	a HER3 promoter construct spanning ~ 1 kb upstream of the transcriptional start site
T23	Parameter 902 913	8505C cells
R18	parameterizes Arg1:T22 Arg2:T21	
R19	parameterizes Arg1:T20 Arg2:T21	
R20	parameterizes Arg1:T23 Arg2:T21	
T24	Parameter 1156 1163	PLX4032
T25	Statistical-Effect 1171 1182	an increase
T26	DepVb 1186 1201	phosphorylation
T27	Parameter 1205 1213	FoxO1/3A
T28	Parameter 1222 1227	4â€“10h
T29	IndepVb 1234 1254	addition of compound
R21	measures Arg1:T28 Arg2:T29	
R22	parameterizes Arg1:T27 Arg2:T26	
R23	parameterizes Arg1:T28 Arg2:T26	
R24	parameterizes Arg1:T24 Arg2:T26	
R25	provides-input-for Arg1:T26 Arg2:T25	
T30	Process 1812 1821	Silencing
T31	Parameter 1825 1830	CtBP1
T32	Parameter 1855 1860	CtBP2
R26	parameterizes Arg1:T31 Arg2:T30	
R27	parameterizes Arg1:T32 Arg2:T30	
T33	Statistical-Effect 1862 1871	increased
T34	DepVb 1872 1882	basal HER3
T35	Parameter 1878 1882	HER3
T36	Entity 1892 1897	cells
T37	Parameter 1886 1891	8505C
R28	parameterizes Arg1:T37 Arg2:T36	
R29	precedes Arg1:T36 Arg2:T30	
R30	parameterizes Arg1:T35 Arg2:T34	
R31	parameterizes Arg1:T37 Arg2:T34	
T38	Statistical-Effect 1903 1923	markedly potentiated
T39	DepVb 1924 1935	the effects
T40	Parameter 1939 1946	PLX4032
R32	parameterizes Arg1:T40 Arg2:T39	
R33	provides-input-for Arg1:T39 Arg2:T38	
T41	Parameter 1978 1991	these factors
T42	Process 1965 1974	Knockdown
R34	parameterizes Arg1:T41 Arg2:T42	
T43	Statistical-Effect 1992 2010	modestly increased
T44	Parameter 2011 2016	basal
T45	Parameter 2021 2036	PLX4032-induced
T46	Parameter 2037 2041	HER2
T47	DepVb 2042 2048	levels
R35	provides-input-for Arg1:T47 Arg2:T43	
R36	parameterizes Arg1:T46 Arg2:T47	
R37	parameterizes Arg1:T45 Arg2:T47	
R38	parameterizes Arg1:T44 Arg2:T47	
T48	Statistical-Effect 2078 2101	the remarkable increase
T49	DepVb 2105 2110	pHER3
R39	provides-input-for Arg1:T49 Arg2:T48	
T50	Parameter 2150 2155	CtBP1
T51	Parameter 2160 2165	CtBP2
T52	Process 2166 2202	chromatin immunoprecipitation assays
T53	Statistical-Effect 2210 2219	decreased
T54	DepVb 2220 2248	binding to the HER3 promoter
R40	provides-input-for Arg1:T54 Arg2:T53	
T55	Process 2255 2264	treatment
T56	Parameter 2270 2277	PLX4032
R41	parameterizes Arg1:T56 Arg2:T55	
R42	precedes Arg1:T55 Arg2:T52	
R43	parameterizes Arg1:T51 Arg2:T52	
R44	parameterizes Arg1:T50 Arg2:T52	
